Abstract: A hybrid vehicle, an air conditioning system and a method for controlling the air conditioning system are provided. The air conditioning system includes: an electric compressor; a mechanical compressor, connected with the electric compressor in parallel; a power battery, connected with the electric compressor and configured to supply power to the electric compressor; an engine, connected with the mechanical compressor and configured to supply a power source to the mechanical compressor; an engine controller, connected with the engine and configured to start the engine when the mechanical compressor is to be started; a battery manager, connected with the power battery and configured to detect a state of charge of the power battery; and a controller, connected with the engine controller and the battery manager and configured to start the electric compressor and the mechanical compressor at different time according to the state of charge of the power battery.

Abstract: A hybrid vehicle, an air conditioning system and a method for controlling the air conditioning system are provided. The air conditioning system includes: an electric compressor; a mechanical compressor, connected with the electric compressor in parallel; a power battery, connected with the electric compressor and configured to supply power to the electric compressor; an engine, connected with the mechanical compressor and configured to supply a power source to the mechanical compressor; an engine controller, connected with the engine and configured to start the engine when the mechanical compressor is to be started; a battery manager, connected with the power battery and configured to detect a state of charge of the power battery; and a controller, connected with the engine controller and the battery manager and configured to start the electric compressor and the mechanical compressor at different time according to the state of charge of the power battery.

Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.

Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.

Abstract: The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.

Abstract: An efficient and simplified method for preparing and sorting fused cells is described herein. This approach yields fused cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract: The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.

Abstract: The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.

Abstract: The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.

Abstract: The invention provides a combined whole cell tumor vaccine for inducing tumor resistance in patients and treating cancer.

Abstract: The present invention relates to cancer treatment compositions and methods for a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation in combination with Mycobacterium bovis bacillus Calmette-Guerin (BCG).

Abstract: The present invention describes a method for targeting a tumor cell comprising contacting the tumor cell with a composition comprising a macrophage and a factor that upregulates nuclear factor-kappa B (NF?B) activity.

Abstract: The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.

Abstract: The invention relates to a pharmaceutical composition, methods for its use and kits comprising the pharmaceutical composition, wherein the composition comprises: (a) a carrier portion; (b) a targeting portion, wherein said targeting portion comprises a targeting peptide; and (c) an immune response triggering portion, wherein said immune response triggering portion triggers a complement mediated hyperacute immune response.

Abstract: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiated, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract: The present invention provides an antitumor agent comprising a targeting portion and an immune response triggering portion. The targeting portion may be an antibody fragment or a tumor vasculature binding peptide. The immune response triggering portion may be an Fc fragment of immunoglobulin G (IgG), a fragment of the Fc fragment of IgG that exhibits the same biological function as the Fc region, or the extracellular domain of foreign major histocompatability complex (MHC). The antitumor agent is useful for inhibiting tumor growth, inhibiting tumor angiogenesis and treating diseases associated with neovascularization.

Abstract: A rapid, simple-to-use method for preparing hybrid cells, applicable to fully differentiate, non-dividing cells, entails bringing at least two different cells into contact under conditions that promote cell fusion and then purifying the resultant hybrid without antibiotic or metabolic selection. This approach yields hybrid cells useful in a variety of applications, including clinical treatment regimens, as cellular modulators of the immune system.

Abstract: The invention relates to a pharmaceutical composition, methods for its use and kits comprising the pharmaceutical composition, wherein the composition comprises: (a) a carrier portion; (b) a targeting portion, wherein said targeting portion comprises a targeting peptide; and (c) an immune response triggering portion, wherein said immune response triggering portion triggers a complement mediated hyperacute immune response.

Abstract: The present invention relates to immunogenic compositions for stimulating T cell proliferation and methods for enhancing therapeutic effectiveness of some traditional anti-cancer treatments. Specifically, local delivery of cytokines that target the plasma membrane of a cancerous cell exhibit more potent anti-tumor effects than systemic delivery of cytokines in soluble form.